Bionomics Limited (BNOX)
0.25
0.01 (3.31%)
At close: Dec 23, 2024, 9:00 PM
3.31% (1D)
| Bid | 0.4 |
| Market Cap | 891.89M |
| Revenue (ttm) | 182.7K |
| Net Income (ttm) | -26.6M |
| EPS (ttm) | -14.32 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | -0.17 |
| Analyst | n/a |
| Ask | 0.4 |
| Volume | 906,395 |
| Avg. Volume (20D) | 875,913 |
| Open | 0.25 |
| Previous Close | 0.24 |
| Day's Range | 0.24 - 0.29 |
| 52-Week Range | 0.24 - 18.00 |
| Beta | -0.07 |
About BNOX
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 16, 2021
Employees 8
Stock Exchange NASDAQ
Ticker Symbol BNOX
Website https://www.bionomics.com.au
4 months ago
+158.52%
Bionomics shares are trading higher after the comp...
Unlock content with
Pro Subscription
5 months ago
-11.2%
Bionomics shares are trading lower. The company shareholders will vote on re-domiciling to the US.
1 year ago · proactiveinvestors.com
Bionomics shares soar almost 400% after positive phase IIb results from PTSD treatmentShares of Bionomics Limited rocketed 387% after phase IIb trial results showed its lead asset had the potential to become a best-in-class treatment for post-traumatic stress disorder (PTSD). Researche...
